Medical
Baptist Health in Jacksonville, Florida did the first operation in a US study (REMIND) testing Symani microsurgery for Alzheimer's and similar brain diseases. The study plans 15 patients.
A dated step forward on the record · Company-reported
What the source says
“MMI expects its first-of-its-kind study to enroll 15 patients and follow them through 12 months post-procedure.”
What it means
Symani, from MMI (Medical Microinstruments), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. Its stage is set by other milestones on its record; this one adds to the history. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Symani
- A new US billing code for lymph-to-vein bypass surgery with robot help (CPT 1019T) was created, taking effect 1 January 2026, so hospitals can bill for these operations.
- Penn Presbyterian Medical Center did the first two US operations with Symani, rebuilding damaged limbs.
- The FDA cleared Symani through the De Novo route (DEN230032) for microsurgery on soft tissue.
- MMI said surgeons had used Symani in nearly 1,000 operations in Europe before the US clearance.